Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct;34(10):1780-1788.
doi: 10.1002/jbmr.3852.

Primary Bone Tumors: Challenges and Opportunities for CAR-T Therapies

Ian W Folkert  1 , Samir Devalaraja  2 , Gerald P Linette  3 , Kristy Weber  4   5 , Malay Haldar  2   5   6
Affiliations
Free article
Review

Primary Bone Tumors: Challenges and Opportunities for CAR-T Therapies

Ian W Folkert et al. J Bone Miner Res. 2019 Oct.
Free article

Abstract

Primary malignant bone tumors are rare, occur in all age groups, and include distinct entities such as osteosarcoma, Ewing sarcoma, and chondrosarcoma. Traditional treatment with some combination of chemotherapy, surgery, and radiation has reached the limit of efficacy, with substantial room for improvement in patient outcome. Furthermore, genomic characterization of these tumors reveals a paucity of actionable molecular targets. Against this backdrop, recent advances in cancer immunotherapy represent a silver lining in the treatment of primary bone cancer. Major strategies in cancer immunotherapy include stimulating naturally occurring anti-tumor T cells and adoptive transfer of tumor-specific cytotoxic T cells. Chimeric antigen receptor T cells (CAR-T cells) belong to the latter strategy and are an impressive application of both insights into T cell biology and advances in genetic engineering. In this review, we briefly describe the CAR-T approach and discuss its applications in primary bone tumors. © 2019 American Society for Bone and Mineral Research.

Keywords: CANCER; OSTEOIMMUNOLOGY; OTHER; PRIMARY TUMORS OF BONE AND CARTILAGE; SYSTEMS BIOLOGY - BONE INTERACTORS; THERAPEUTICS.

PubMed Disclaimer

References

    1. Gorlick R, Khanna C. Osteosarcoma. J Bone Miner Res. 2010;25(4):683-91.
    1. Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer. 2009;125(1):229-34.
    1. Martin JW, Squire JA, Zielenska M. The genetics of osteosarcoma. Sarcoma. 2012;2012:627254.
    1. Selvarajah S, Yoshimoto M, Maire G, et al. Identification of cryptic microaberrations in osteosarcoma by high-definition oligonucleotide array comparative genomic hybridization. Cancer Genet Cytogenet. 2007;179(1):52-61.
    1. Miwa S, Shirai T, Yamamoto N, et al. Current and emerging targets in immunotherapy for osteosarcoma. J Oncol. 2019;2019:7035045.

MeSH terms

Substances